Abstract
Background: Though patient needs are key drivers of treatment decisions, they are rarely systematically investigated in routine care. Objective: This study aimed at analysing needs and expectations from the patient perspective in the German and Swiss psoriasis registries PsoBest and Swiss Dermatology Network of Targeted Therapies (SDNTT) with respect to treatment choice, age and gender. Methods: The German and Swiss psoriasis registries observe patients recruited at first-time use of systemic drugs. Within 10 years, clinical [Psoriasis Area Severity Index (PASI), Body Surface Area (BSA)] and patient-reported outcomes are documented, including the Dermatology Quality of Life Index (DLQI) and the Patient Benefit Index (PBI), characterizing patient needs for treatment. The analysis data set includes n = 4894 patients from PsoBest and n = 449 from SDNTT with mean follow-up time of 7.5 months. Results: A total of 5343 patients registered between 2008 and 2016 were included in the analyses (at baseline: 59.6% male, mean age 47.6 years ± 14.5, PASI 14.2 ± 9.7, BSA 22.7 ± 19.7, DLQI 11.3 ± 7.2). The most important patient needs were to ‘get better skin quickly’ and to ‘be healed of all skin defects’. Subgroup analyses by age revealed significant differences in needs, especially higher needs regarding social impairments in patients younger than 65 years. Patients 65 years or older attributed more importance to sleep quality, less dependency on medical visits, fewer side-effects and confidence in the therapy. Out of 25 items reflecting patient needs, 20 items were rated significantly more important by women than men, with the greatest differences regarding feeling of depression, sleep quality and everyday productivity. Divided by treatment, needs were rated differently, recommending individualized and targeted choice of therapy. Conclusion: Age and gender stratify patient needs. Women showed higher expectations and rated specific needs in psoriasis treatment higher than men. Analysing the patient needs on an individual level will facilitate shared decisions by patient and physician in finding the optimal personalized treatment.
| Original language | English |
|---|---|
| Journal | Journal of the European Academy of Dermatology and Venereology |
| Volume | 33 |
| Issue number | 4 |
| Pages (from-to) | 700-708 |
| Number of pages | 9 |
| ISSN | 0926-9959 |
| DOIs | |
| Publication status | Published - 04.2019 |
Funding
Maul J-T is an employee of USZ and holds a ‘Filling the GAP’ scholarship. Navarini AA is funded by the Promedica and Bruno-Bloch Foundation, as well as Hochspezialisierte Medizin 2 of the Kanton Zu€rich, Switzerland. He is also on the advisory board of AbbVie, Pfizer, Novartis, Celgene, MSD, Galderma. Sommer R, Mrowietz U, Thaci D, Streit M, Borradori L, Gilliet M and Itin P have no conflict of interest. Anzengruber F has been awarded a competitive grant from the University of Zurich (Forschungskredit). He has received honoraria from Abbvie, Celgene, Leo Pharma, Galderma and Novartis, but has no financial interest, nor holds any shares of any pharmaceutical company. Sorbe C is an employee of UKE. Drach M has received financial compensation for consultancy and/or lecture activities from Abbvie, Janssen-Cilag, Novartis, Leo Pharma and Almirall. Blome C has received speaker honoraria, research grants, awards and/or travel expenses from Celgene, Janssen-Cilag, Kreussler, Lilly, Mapi Group, medi, Stiefel Laboratories, The EuroQol Group, and Urgo and is an employee of UKE. Boehncke WH has received honoraria as a speaker or advisor from Abbvie, Almirall, BMS, Celgene, Janssen, Leo, Lilly, Novartis, UCB. He has received a research grant from Pfizer to study the role of JAK inhibition in psoriasis. Reich K has served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by Abbvie, Affibody, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Kyowa Kirin, Leo, Lilly, Medac, Merck Sharp & Dohme, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Takeda, UCB, Valeant, Xenoport. von Kiedrowski R has served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, ALK Scherax, Almirall Hermal, Biofrontera, Biogen, Boehringer, Celgene, Dr. Pfleger, Foamix, Hexal, Janssen-Cilag, LEO, Lilly, Medac, Menlo, MSD, Novartis, Pfizer, Regeneron, Sanofi-Aventis, Stallergenes, Stiefel GSK, Tigercat and UCB. Ko€rber A has received research grants and/or consulting or lecturing fees from Abbvie, Almirall, Biogen, Bo€hringer, Celgene, Eli Lilly, Janssen-Cilag, Leo, Merck, MSD, Novartis, Pfizer, UCB. Yawalkar N has received honoraria for consulting and advisory board attendance from Abbvie, Almirall, Amgen, Celgene, Eli Lilly, Galderma, Janssen, Leo, Novartis, MSD and Pfizer. Mainetti has received honoraria for Advisory Boards from LEO Pharma, AbbVie, Almirall, Celgene, and Eli Lilly. Laffitte E has received honoraria for consulting and advisory board attendance from Abbvie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, Leo, Novartis, MSD and Pfizer. Rustenbach S is an employee of UKE. Conrad C has served as a scientific adviser and/or clinical study investigator and/or paid speaker for AbbVie, Actelion, Amgen, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, and Pfizer. Cozzio A has received honoraria for Advisory Boards regarding psoriasis from AbbVie, Celgene, Eli Lilly, Janssen-Cilag and Novartis. Ha€usermann P has received honoraria for Advisory Boards regarding psoriasis from AbbVie, Almirall, Celgene, Eli Lilly, Galderma, Janssen-Cilag and Novartis. French LE has received honoraria for consulting and advisory board attendance from Abbvie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, Leo, Novartis and Pfizer. Radtke MA has received research grants and/or consulting or lecturing fees from Abbvie, Almirall, Amgen, Astellas, Biogen, Biologix, Bo€hringer, Celgene, Eli Lilly, Galderma, Hexal, Janssen-Cilag, La Roche Posay, Leo, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz, Sanofi. Augustin M has received research grants and/or consulting or lecturing fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Hexal, Janssen-Cilag, Leo, Medac, MSD, Mundipharma, Novartis, Pfizer, Sandoz and Xenoport. The registries are supported by AbbVie, Amgen, Almirall, Biogen, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Novartis and Pfizer. These companies do not have any influence on design of the register, data collection and analyses as well as on publication decisions or manuscript constructions.
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
